Investor Relations

EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained-delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU® (dexamethasone intraocular suspension) 9%, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Recent Releases

May 26, 2021
EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

Learn More

May 25, 2021
EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD

Learn More

May 05, 2021
EyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate Developments
Learn More

April 28, 2021
EyePoint Pharmaceuticals to Report First Quarter 2021 Financial Results and Discuss Recent Corporate Developments on May 5, 2021
Learn More

Mar 04, 2021
EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Corporate Developments
Learn More

Feb 25, 2021
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Learn More

Feb 25, 2021
EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
Learn More

Feb 04, 2021
EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock
Learn More

Feb 01, 2021
EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Learn More

Feb 01, 2021
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Learn More

Events & Presentations

Building value through innovation, dedicated to making a difference.

IR CONTACTS
Stern Investor Relations
p. 212.362.1200
e. eyepoint@sternir.com

MEDIA RELATIONS CONTACT
Caren Begun
p. 973.263.8585
e. caren@greenroompr.com